Real World Efficiency of Abrocitinib Treatment at Patients With Moderate to Severe Atopic Dermatitis Who Had Inadequate Response to Previous Biologic Therapies.

Part of paid clinical trials in New York, New York.

Sponsor
Pfizer
Study ID
NCT06899204
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Abrocitinib — DRUG
    Study Drug for Observational Data Collection.

Study Details

This is a prospective, multi-center observational study characterizing clinical and patient reported outcomes of patients receiving abrocitinib for moderate-to-severe atopic dermatitis (M2S AD) who had inadequate response (or intolerance) to ≤2 previous biologic therapies approved for M2S AD in the United States. The aim of this study is to measure the effectiveness of abrocitinib in a real-world setting in patients with moderate-to-severe atopic dermatitis, with inadequate response or intolerance to ≤2 biologic therapies.

Key Dates

Start date
Jan 13, 2026
Status verified
Apr 2026
Primary completion
Jul 1, 2026
Completion
Feb 15, 2027

Study Design

Enrollment
150 participants (estimated)

Arms

  • Arm: Treatment
    Patients that are taking treatment with abrocitinib for moderate to severe atopic dermatitis.

Primary Outcome Measure

Percentage of patients achieving EASI-75 improvement from baseline at Week 16 after index date [ Time Frame: Baseline, week 16 ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
PfizerNew YorkNew York10001-

Find similar trials in New York, NY

By condition
Atopic dermatitis / eczema
By specialty
DermatologyRheumatologyAutoimmune disease
By research site
Pfizer· New York, NY

Related Studies